Your browser doesn't support javascript.
loading
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection.
Domnich, Alexander; Orsi, Andrea; Signori, Alessio; Chironna, Maria; Manini, Ilaria; Napoli, Christian; Rizzo, Caterina; Panatto, Donatella; Icardi, Giancarlo.
Affiliation
  • Domnich A; Hygiene Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy.
  • Orsi A; Hygiene Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy.
  • Signori A; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
  • Chironna M; Interuniversity Research Centre on Influenza and Other Transmissible Infections (CIRI-IT), Genoa, Italy.
  • Manini I; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
  • Napoli C; Interdisciplinary Department of Medicine, University of Bari, Bari, Italy.
  • Rizzo C; Interuniversity Research Centre on Influenza and Other Transmissible Infections (CIRI-IT), Genoa, Italy.
  • Panatto D; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
  • Icardi G; Sant'Andrea Hospital, University La Sapienza, Rome, Italy.
Expert Rev Vaccines ; 23(1): 380-388, 2024.
Article in En | MEDLINE | ID: mdl-38494919
ABSTRACT

BACKGROUND:

The question of whether influenza vaccine effectiveness (VE) wanes over the winter season is still open and some contradictory findings have been reported. This study investigated the possible decline in protection provided by the available influenza vaccines. RESEARCH DESIGN AND

METHODS:

An individual-level pooled analysis of six test-negative case-control studies conducted in Italy between the 2018/2019 and 2022/2023 seasons was performed. Multivariable logistic regression analyses were performed to estimate weekly change in the odds of testing positive for influenza 14 days after vaccination.

RESULTS:

Of 6490 patients included, 1633 tested positive for influenza. Each week that had elapsed since vaccination was associated with an increase in the odds of testing positive for any influenza (4.9%; 95% CI 2.0-8.0%) and for A(H3N2) (6.5%; 95% CI 2.9-10.3%). This decline in VE was, however, significant only in children and older adults. A similar increase in the odds of testing positive was seen when the dataset was restricted to vaccinees only. Conversely, VE waning was less evident for A(H1N1)pdm09 or B strains.

CONCLUSIONS:

Significant waning of VE, especially against influenza A(H3N2), may be one of the factors associated with suboptimal end-of-season VE. Next-generation vaccines should provide more durable protection against A(H3N2).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / Influenza A Virus, H1N1 Subtype Limits: Aged / Child / Humans Language: En Journal: Expert Rev Vaccines Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article Affiliation country: Italia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / Influenza A Virus, H1N1 Subtype Limits: Aged / Child / Humans Language: En Journal: Expert Rev Vaccines Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article Affiliation country: Italia